Research Topics
| Joseph K SalamaSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort studyAbhishek A Solanki
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, 5758 South Maryland Ave, MC 9006, Chicago IL 60637, US
Radiat Oncol 7:216. 2012..However, the characterization of PET response following SBRT is unknown in this population. We analyzed our cohort of patients to describe the PET response following SBRT...
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic diseaseJoseph K Salama
Department of Radiation Oncology, Duke University, Durham, North Carolina 27710, USA
Cancer 118:2962-70. 2012..A subset of patients with metastatic cancer in limited organs may benefit from metastasis-directed therapy. The authors investigated whether patients with limited metastases could be safely treated with metastasis-directed radiotherapy...- ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neckJoseph K Salama
Duke University, Durham, NC, United States
Oral Oncol 47:554-9. 2011..Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients... - Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia GrouJoseph K Salama
Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 81:e269-74. 2011..We conducted a secondary analysis of all patients to determine predictors of treatment-related pulmonary toxicity... - A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancersJ K Salama
Department of Radiation Oncology, Duke University, Durham 27710, USA
Ann Oncol 22:2304-9. 2011..We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX) for intermediate-stage and select T4 head and neck squamous cell cancers (HNSCC)... - Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiationKevin S Choe
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA
Cancer 117:4671-8. 2011..To examine potential prognostic factors associated with survival, the authors of this report retrospectively reviewed the outcomes of patients who received CReRT... - Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignanciesAaron W Pederson
Department of Radiation Oncology, Memorial University Medical Center, 4700 Waters Avenue, Savannah, GA 31404, USA
Head Neck Oncol 3:31. 2011..To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy... - Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancerKevin S Choe
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA
Radiother Oncol 97:318-21. 2010..In the postoperative setting, the efficacy of such an approach with adjuvant chemotherapy (AdjCT) followed by postoperative CCRT is unclear... - Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancerKent W Mouw
Department of Radiation Oncology, Duke University Medical Center, PO Box 3085, Durham, NC 27710, USA
Arch Otolaryngol Head Neck Surg 136:1226-34. 2010..to identify factors that influence patient-centered measures of speech and swallowing function after successful use of chemoradiotherapy to treat cancers of the head and neck... - Predictors of competing mortality in advanced head and neck cancerLoren K Mell
University of California San Diego, Moores Cancer Center, Department of Radiation Oncology, 3855 Health Sciences Dr MC 0843, La Jolla, CA 92129, USA
J Clin Oncol 28:15-20. 2010..Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials... - Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancerMichael D Hasselle
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA
J Thorac Oncol 7:376-81. 2012..Outcomes data treating patients with oligometastatic (≤ 5 metastases) non-small cell lung carcinoma (NSCLC) with hypofractionated image-guided radiotherapy (HIGRT) are limited...